Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis

References

• Lewiecki EM, Gordon CM, Baim S, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone 2008;43:1115-21
   PubMed Web of Science ®Google Scholar
• Orimo H, Hayashi Y, Fukunaga M, et al. Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001;19:331-7
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Kiwaki K, Inomoto T, et al. Bone mineral density of the lumbar spine and total body mass in Japanese children and adolescents. J Jpn Pediatr Soc 1999;103:69-76
   Google Scholar
• Bartlett DJ, Hanna SE, Avery L, et al. Correlates of decline in gross motor capacity in adolescents with cerebral palsy in Gross Motor Function Classification System levels III to V: an exploratory study. Dev Med Child Neurol 2010;52:e155-60
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006-13
   PubMed Web of Science ®Google Scholar
• Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50
   PubMed Web of Science ®Google Scholar
• Kelly HW, Van Natta ML, Covar RA, et al. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the Childhood Asthma Management Program (CAMP) study. Pediatrics 2008;122:e53-61
   PubMed Web of Science ®Google Scholar
• Homik JE, Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999;26:1148-57
   PubMed Web of Science ®Google Scholar
• Shoemaker LR. Expanding role of bisphosphonate therapy in children. J Pediatr 1999;134:264-7
   PubMed Web of Science ®Google Scholar
• Noguera A, Ros JB, Pavia C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003;16:529-36
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11
   PubMed Web of Science ®Google Scholar
• Andress DL, Ozuna J, Trischwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-6
   PubMed Web of Science ®Google Scholar
• Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999;38:93-8
   PubMed Web of Science ®Google Scholar
• Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42:1141-7
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Takei K, Nakamura S, et al. Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatr Int 2008;50:269-75
   PubMed Web of Science ®Google Scholar
• Houlihan CM, Stevenson RD. Bone density in cerebral palsy. Phys Med Rehabil Clin N Am 2009;20:493-508
   PubMed Web of Science ®Google Scholar
• Ali O, Shim M, Fowler E, et al. Growth hormone therapy improves bone mineral density in children with cerebral palsy: a preliminary pilot study. J Clin Endocrinol Metab 2007;92:932-7
   PubMed Web of Science ®Google Scholar
• Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002;110:e5
   PubMed Web of Science ®Google Scholar
• Sheth RD. Bone health in pediatric epilepsy. Epilepsy Behav 2004;5:S30-35
   PubMed Web of Science ®Google Scholar
• Costa AM, Lemos-Marini SH, Baptista MT, et al. Bone mineralization in Turner syndrome: a transverse study of the determinant factors in 58 patients. J Bone Miner Metab 2002;20:294-7
   PubMed Web of Science ®Google Scholar
• van den Berg LE, Zandbergen AA, van Capelle CI, et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. Bone 2010;47:643-9
   PubMed Web of Science ®Google Scholar
• van Kuijk C. Pediatric bone densitometry. Radiol Clin North Am 2010;48:623-7
   PubMed Web of Science ®Google Scholar
• Tsukahara H, Kimura K, Todoroki Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002;44:247-53
   PubMed Web of Science ®Google Scholar
• Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998;102:990-3
   PubMed Web of Science ®Google Scholar
• Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 1993;43:416-17
   PubMed Web of Science ®Google Scholar
• Kubota M, Nishi-Nagase M, Sakakihara Y, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 2000;22:230-3
   PubMed Web of Science ®Google Scholar
• Hayashi A, Hanada T, Kohda T, et al. Three cases of urolithiasis during treatment with zonisamide. J Jpn Pediatr Nephrol 2005;18:27-31
   Google Scholar
• Bogunovic L, Doyle SM, Vogiatzi MG. Measurement of bone density in the pediatric population. Curr Opin Pediatr 2009;21:77-82
   PubMed Web of Science ®Google Scholar
• Fowler EG, Kolobe TH, Damiano DL, et al. Promotion of physical fitness and prevention of secondary conditions for children with cerebral palsy: section on pediatrics research summit proceedings. Phys Ther 2007;87:1495-510
   PubMed Web of Science ®Google Scholar
• Guadalix S, Martínez-Díaz-Guerra G, Lora D, et al. Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transpl Int 2011;24:657-65
   PubMed Web of Science ®Google Scholar
• Barbour KE, Zmuda JM, Boudreau R, et al. The effects of adiponectin and leptin on changes in bone mineral density. Osteoporos Int 2011: published online 30 August 2011, doi 10.1007/s00198-011-1768-x
   Google Scholar
• Mimouni FB, Shamir R. Vitamin D requirements in the first year of life. Curr Opin Clin Nutr Metab Care 2009;12:287-92
   PubMed Web of Science ®Google Scholar
• Marini JC. Do bisphosphonates make children’s bones better or brittle? N Engl J Med 2003;349:423-6
   PubMed Web of Science ®Google Scholar